secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2023-06-12T23:59:59+00:00
Accession:  0000950170-23-027374
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron Therapeutics appoints William Forbes as Chief Development Officer; authorized shares increased to 225M
--------------------------------------------------------------------------------

- Kimberly Manhard resigned as EVP, Drug Development effective June 6, 2023, amicably; replaced by William Forbes, Pharm.D., as EVP, Chief Development Officer.
- Forbes received inducement grants: option for 500K shares, 50K RSUs, and performance option for 700K shares tied to stock price goals.
- Stockholders approved charter amendment increasing authorized common shares from 150M to 225M, effective June 9, 2023.
- All six proposals at 2023 Annual Meeting passed, including director elections, auditor ratification, and equity plan amendments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000095017023027374/0000950170-23-027374-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000095017023027374/hrtx-20230606.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-027374

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer